Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001052875 | SCV001217109 | pathogenic | Hereditary breast ovarian cancer syndrome | 2022-10-13 | criteria provided, single submitter | clinical testing | This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Glu2183Asnfs*8) in the BRCA2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA2 are known to be pathogenic (PMID: 20104584). This premature translational stop signal has been observed in individual(s) with breast or ovarian cancer (PMID: 28294317, 30078507). For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 849000). |
Color Diagnostics, |
RCV001524607 | SCV001734529 | pathogenic | Hereditary cancer-predisposing syndrome | 2020-11-30 | criteria provided, single submitter | clinical testing | This variant deletes 1 nucleotide in exon 11 of the BRCA2 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with breast or ovarian cancer (PMID: 28294317, 28664449, 30078507). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. |